A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study evaluating the efficacy and safety of CNTO 148 administered subcutaneously in symptomatic subjects with severe persistent asthma
Laufzeit: 01.01.2004 - 31.12.2007